Lin Shen
Led the CT041 trials that produced the first CAR-T therapy approved for a solid tumour, in gastric cancer.
Lin Shen's group at Peking University Cancer Hospital ran the phase 1 and randomised phase 2 trials of satricabtagene autoleucel (CT041, Claudin 18.2 CAR-T) and leads Chinese gastric cancer immunotherapy and HER2 studies.
| Title | Journal | Year |
|---|---|---|
| Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results | Nature Medicine | 2022 |
Patients with newly diagnosed metastatic colorectal cancer whose tumour carries a BRAF V600E mutation, which is about 8-12% of cases, should now be offered encorafenib and cetuximab together with FOLFOX from the start rather than after chemotherapy fails; median survival has roughly doubled to about two and a half years. BRAF testing at diagnosis is therefore essential, alongside RAS and mismatch repair testing. The regimen is more toxic than chemotherapy alone.
Patients with newly diagnosed advanced stomach or oesophageal adenocarcinoma whose tumour is HER2-negative and PD-L1 positive (CPS 5 or more, or at least 1 in some regions) should receive chemotherapy with nivolumab (or pembrolizumab, from KEYNOTE-859), which adds about three months of median survival and doubles the chance of being alive at three years. The benefit in PD-L1-negative tumours is doubtful, and these patients may be better served by chemotherapy alone or by trials.